- Home
- VRTX vs CRWD Comparison
VRTX vs CRWD Comparison
Compare VRTX & CRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- CRWD
- Stock Information
- Founded
- VRTX 1989
- CRWD 2011
- Country
- VRTX United States
- CRWD United States
- Employees
- VRTX N/A
- CRWD N/A
- Industry
- VRTX EDP Services
- CRWD EDP Services
- Sector
- VRTX Technology
- CRWD Technology
- Exchange
- VRTX Nasdaq
- CRWD Nasdaq
- Market Cap
- VRTX 115.6B
- CRWD 123.7B
- IPO Year
- VRTX 1991
- CRWD 2019
- Fundamental
- Price
- VRTX $470.43
- CRWD $478.11
- Analyst Decision
- VRTX Buy
- CRWD Buy
- Analyst Count
- VRTX 25
- CRWD 48
- Target Price
- VRTX $508.91
- CRWD $453.98
- AVG Volume (30 Days)
- VRTX 1.3M
- CRWD 3.2M
- Earning Date
- VRTX 08-04-2025
- CRWD 08-27-2025
- Dividend Yield
- VRTX N/A
- CRWD N/A
- EPS Growth
- VRTX N/A
- CRWD N/A
- EPS
- VRTX N/A
- CRWD N/A
- Revenue
- VRTX $11,099,700,000.00
- CRWD $4,136,022,000.00
- Revenue This Year
- VRTX $10.48
- CRWD $23.38
- Revenue Next Year
- VRTX $10.69
- CRWD $21.77
- P/E Ratio
- VRTX N/A
- CRWD N/A
- Revenue Growth
- VRTX 8.98
- CRWD 25.94
- 52 Week Low
- VRTX $377.85
- CRWD $200.81
- 52 Week High
- VRTX $519.88
- CRWD $517.98
- Technical
- Relative Strength Index (RSI)
- VRTX 60.14
- CRWD 48.58
- Support Level
- VRTX $455.79
- CRWD $497.74
- Resistance Level
- VRTX $484.56
- CRWD $514.50
- Average True Range (ATR)
- VRTX 8.51
- CRWD 15.34
- MACD
- VRTX 3.43
- CRWD -3.09
- Stochastic Oscillator
- VRTX 68.83
- CRWD 36.93
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.